Unit
Rheumatologie
RHEUMA · Dept. I
Boehringer Ingelheim BI1366-0031_456906_SSc
May 22, 2023A Phase II, randomised, placebo-controlled, double-blind, parallel-group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with early progressive diffuse cutaneous systemic sclerosis
Clinical Studies - May 22, 2023 - May 22, 2026
Ongoing
Project leader: Rubbert-Roth Andrea
Members: Schmiedeberg Kristin, Bartz-Batliner Mira, Peischl Shirin, Gostic Dragana
Acceleron_A1334-02
Apr 14, 2023A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of ACE-1334 Plus Standard of Care in Participants with Systemic Sclerosis
Clinical Studies - Apr 14, 2023 - Apr 14, 2026
Ongoing
Project leader: Rubbert-Roth Andrea
Members: Schmiedeberg Kristin, Bartz-Batliner Mira, Peischl Shirin, Gostic Dragana
Novartis_CAIN457C22301
Mar 10, 2023A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase3 trial to evaluate efficacy and safety of secukinumab administered subcutaneously versus placebo,in combination with a glucocorticoid taper regimen, in patients with po...
Clinical Studies - Mar 10, 2023 - Mar 10, 2026
Ongoing
Project leader: Rubbert-Roth Andrea
Members: Schmiedeberg Kristin, Bartz-Batliner Mira, Peischl Shirin, Gostic Dragana
Novartis_CLNA043A12203
Dec 30, 2022A randomized, four-arm, canakinumab placebo-controlled, participant, investigator and sponsor-blinded study investigating the safety, tolerability and efficacy of intra-articular canakinumab followed by intra-articular LNA043 in patients with knee os...
Clinical Studies - Dec 30, 2022 - Dec 31, 2025
Ongoing
Project leader: Rubbert-Roth Andrea
Members: Schmiedeberg Kristin, Peischl Shirin, Bartz-Batliner Mira, Peischl Riana, Hutz Carina Liane
Horizon_HZNP-HZN-825-301
Nov 30, 2022A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis
Clinical Studies - Nov 30, 2022 - Dec 31, 2025
Ongoing
Project leader: Rubbert-Roth Andrea
Members: Schmiedeberg Kristin, Peischl Shirin, Peischl Riana, Bartz-Batliner Mira, Hutz Carina Liane
Athena-SSc-ILD-Study
Aug 23, 2022A double blind, randomized, placebo-controlled study to evaluate the efficacy and safety of PRA023 in Subject with Systemic Sclerosis associated with interstitial Lung Disease.
Clinical Studies - Aug 23, 2022 - Aug 23, 2024
Automatically Closed
Project leader: Rubbert-Roth Andrea
Members: Peischl Riana, Peischl Shirin, Bartz-Batliner Mira, Hutz Carina Liane, Schmiedeberg Kristin
Retinale endotheliale Dysfunktion bei Raynaud-Phänomen
Jun 1, 2022Untersuchung der Endothelfunktion retinaler Gefässe bei Patienten mit einem Raynaud Phänomen mit dem Ziel, Veränderungen im Vergleich zu gesunden Menschen darzustellen und Beziehungen zwischen Parametern der retinalen Endothelfunktion, der Kapillarmi...
Clinical Studies - Jun 1, 2022 - Jun 30, 2025
Ongoing
Project leader: Neumann Thomas
Members: Todorova Margarita, Güsewell Sabine
BMS_IM101-863
Jan 24, 2022A Phase 3, Randomized, Head-to-head, Single-blind Study to Compare the Response to Treatment with Subcutaneous Abatacept vs Adalimumab, on Background Methotrexate, in Adults with Early, Seropositive Rheumatoid Arthritis Who Have "Shared Epitope" HLA...
Clinical Studies - Jan 24, 2022 - Jan 17, 2025
Completed
Project leader: Rubbert-Roth Andrea
Members: Peischl Shirin, Peischl Riana, Bartz-Batliner Mira, Haller Christoph, Pirker Ian, Hutz Carina Liane
Novartis CAIN457R12301
Jan 1, 2022A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to investigate the efficacy and safety of secukinumab 300 mg and 150 mg administered subcutaneously versus placebo, in combination with a glucocorticoid taper...
Clinical Studies - Jan 1, 2022 - Jan 1, 2025
Ongoing
Project leader: Rubbert-Roth Andrea
Members: Schmiedeberg Kristin, Bartz-Batliner Mira, Peischl Shirin, Gostic Dragana
AbbVie UPSTAND P20-410 SLEESPA
Dec 10, 2021Real World Effectiveness of Upadacitinib on Early and Sustained Pain Control and Sleep Quality in Radiographic Axial Spondyloarthritis
Clinical Studies - Dec 10, 2021 - Dec 10, 2024
Ongoing
Project leader: Rubbert-Roth Andrea
Members: Bartz-Batliner Mira, Peischl Shirin, Peischl Riana, Hutz Carina Liane
Amgen 20200234
Sep 8, 2021A Phase 2b Dose Ranging Study to Evaluate the Efficacy and Safety of Efavaleukin Alfa in Subjects with Active Systemic Lupus Erythematosus With Inadequate Response to Standard of Care Therapy.
Clinical Studies - Sep 8, 2021 - Apr 6, 2023
Aborted
Project leader: Rubbert-Roth Andrea
Members: Peischl Riana
RECOVER: Rheumatoid Covid-19 Vaccine Immune Response
Feb 1, 2021Untersuchung der Sicherheit und Effektivität von mRNA basierten COVID-19 Impfungen bei Patienten mit rheumatoider Arthritis - ein exploratives Forschungsprojekt
Clinical Studies - Feb 1, 2021 - Dec 31, 2022
Completed
Project leader: Rubbert-Roth Andrea
Members: Schmiedeberg Kristin, Bartz-Batliner Mira, Peischl Riana, Peischl Shirin, Sasselli Clelia, Hutz Carina Liane
IFX-1-P2.5
Nov 1, 2020a randomized, double-blind, double-dummy, active-controlled, multicenter, 2-part Phase 2 study on replacement of steroids by IFX-1 in active granulomatosis with polyangiitis (GPA) and microscopic polyangitis (MPA)
Clinical Studies - Nov 1, 2020 - Nov 1, 2021
Completed
Project leader: Neumann Thomas
Members: Peischl Riana, Rubbert-Roth Andrea
I4V-MC-JAIM
Aug 12, 2020a phase 3, double-blind, multicenter study of evaluate the long-term safety and efficacy of baricitinib in patients with SLE.
Clinical Studies - Aug 12, 2020 - Aug 12, 2022
Completed
Project leader: Rubbert-Roth Andrea
Members: Peischl Riana, Bartz-Batliner Mira
Abbvie UPHOLD P20-095 SLEERA
Aug 1, 2020Upadacitinib treatment patterns, achievement of treatment targets and maintenance of response in moderate to severe Rheumatoid Arthritis patients in real-world practice
Clinical Studies - Aug 1, 2020 - Oct 31, 2023
Automatically Closed
Project leader: Rubbert-Roth Andrea
Members: Bartz-Batliner Mira, Hutz Carina Liane, Peischl Riana, Peischl Shirin, Schmiedeberg Kristin
CAIN457Q12301
Jul 13, 2020A two-year, phase III randomized, double-blind, parallel- group, placebo- controlled trial to evaluate the safety, efficacy, and tolerability of 300 mg s.c. secukinumab versus placebo in combination with SoC therapy in patients with active lupus neph...
Clinical Studies - Jul 13, 2020 - Jul 12, 2023
Automatically Closed
Project leader: Rubbert-Roth Andrea
Members: Bartz-Batliner Mira, Hutz Carina Liane, Peischl Riana, Sasselli Clelia
IgPro20_3007: RECLAIM
Feb 5, 2020A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra®) in Adults with Dermatomyositis (DM)
Clinical Studies - Feb 5, 2020 - Dec 30, 2025
Ongoing
Project leader: Rubbert-Roth Andrea
Members: Hutz Carina Liane, Bartz-Batliner Mira, Peischl Riana, Sasselli Clelia
RA Bridge
Oct 3, 2019A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients with Rheumatoid Arthritis
Clinical Studies - Oct 3, 2019 - Jul 30, 2023
Automatically Closed
Project leader: Rubbert-Roth Andrea
Members: Bartz-Batliner Mira, Neumann Thomas, Sasselli Clelia, Peischl Riana
Amgen CC-10004-PsA-014 MOSAIK
Jul 31, 2019A PHASE 4, MULTICENTER, SINGLE-ARM, OPENLABEL STUDY TO EVALUATE THE IMPACT OF APREMILAST (CC-10004) ON MRI OUTCOMES IN SUBJECTS WITH PSORIATIC ARTHRITIS
Clinical Studies - Jul 31, 2019 - Aug 31, 2021
Completed
Project leader: Rubbert-Roth Andrea
Members: Bartz-Batliner Mira, Neumann Thomas, Sasselli Clelia, Peischl Riana
Sanofi PMR EFC15160
Jul 4, 2019A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with polymyalgia rheumatica
Clinical Studies - Jul 4, 2019 - Jul 8, 2021
Automatically Closed
Project leader: Rubbert-Roth Andrea
Members: Neumann Thomas, Bartz-Batliner Mira, Peischl Riana, Sasselli Clelia